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Abstract Telomerase-targeted therapy for cancer has re-
ceived great attention because telomerase is expressed in al-
most all cancer cells but is inactive in most normal somatic
cells. This study was aimed to investigate the effects of telo-
merase inhibitor MST-312, a chemically modified derivative
of epigallocatechin gallate (EGCG), on acute promyelocytic
leukemia (APL) cells. Our results showed that MST-312
exerted a dose-dependent short-term cytotoxic effect on APL
cells, with G2/M cell cycle arrest. Moreover, MST-312 in-
duced apoptosis of APL cells in caspase-mediated manner.
Telomeric repeat amplification protocol (TRAP) assay re-
vealed significant reduction in telomerase activity of APL
cells following short-term exposure to MST-312. Interesting-
ly, MST-312-induced telomerase inhibition was coupled with
suppression of NF-κB activity as evidenced by inhibition of
IκBα phosphorylation and its degradation and decreased
NF-κB DNA binding activity. In addition, gene expression
analysis showed downregulation of genes regulated by
NF-κB, such as antiapoptotic (survivin, Bcl-2, Mcl-1), prolif-
erative (c-Myc), and telomerase-related (hTERT) genes. Im-
portantly, MST-312 did not show any apoptotic effect in nor-
mal human peripheral blood mononuclear cells (PBMCs). In
conclusion, our data suggest that dual inhibition of telomerase
activity and NF-κB pathway by MST-312 represents a novel
treatment strategy for APL.
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Introduction
Acute promyelocytic leukemia (APL), a unique subtype of
acute myelogenous leukemia (AML), is characterized by a
specific chromosomal translocation t(15;17), which fuses the
promyelocytic leukemia (PML) gene to retinoic acid receptor
(RARα) gene. The PML-RARα fusion gene plays a central
role in leukemogenesis, including arrest of differentiation and
evasion of apoptosis [1, 2]. One of the most important hall-
marks of tumor cells is deregulation of signaling pathways
that contribute to tumor formation and progression as well as
tumor resistance to chemotherapeutic agents. Therefore, iden-
tification of the molecular mechanisms that contribute to tu-
mor survival and apoptosis is of great importance for rational
development of molecular targeted therapies [3–5].
The telomerase holoenzyme, composed of both RNA sub-
unit (hTR or hTERC) and catalytic subunit (hTERT), main-
tains telomere length through reverse transcriptase activity [6,
7]. Telomerase activity is suppressed during embryonic differ-
entiation but remains active in highly proliferative cells such
as stem cells and germ cells. Reactivation of telomerase has
been observed in 90 % of all human cancers, suggesting that
its activation is a critical step in human carcinogenicity [8, 9].
Although telomerase overcomes replicative crisis by regula-
tion of telomere length, upregulation of its activity in cancer
cells promotes cell proliferation, invasion, and resistance to
apoptosis. Increasing evidence has highlighted non canonical
(non-telomeric) activities of telomerase that are independent
of its conventional function in telomere maintenance [10–12].
These activities included regulation of cell cycle [13], regula-
tion of gene expression [12, 14, 15], inhibition of apoptosis
[16–18], and modulation of cellular signaling [19, 20].
The nuclear factor-κB (NF-κB) signaling pathway plays a
key role in regulating cellular and developmental events. This
pathway is commonly deregulated in human cancers and can
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affect main features of cancer such as proliferation, survival,
apoptosis resistance, angiogenesis, metastasis, and inflamma-
tion through transcriptional activation of the genes involved in
these processes [21–23]. Upregulation of anti-apoptotic
NF-κB target genes is a key mechanism in evasion of apopto-
sis in cancers with constitutively activated NF-κB signaling
pathway [24, 25]. Intriguingly, the mechanisms underlying the
constitutive NF-κB activation are poorly understood and like-
ly to be important in cancer development and progression.
Given that both telomerase and NF-κB are hyperactivated in
a wide variety of cancers, interaction between themmight be a
key missing molecular link that less well appreciated.
Telomerase-targeted therapy for cancer has received great
attention because telomerase is expressed in almost all cancer
cells but is inactive in most normal somatic cells [26]. Although
stem cells in regenerative tissues also express telomerase, the
effect of telomerase inhibition on these cells seem to be minor
because they havemuch longer initial telomeres compared with
cancer cells. Actually, the responsiveness and the time needed
for effect of telomerase inhibition on growth arrest or cell death
would be different based on initial telomere length of target
cells: The longer the telomere, the later the effect [27, 28].
Consistently, cancer cells with varying telomere lengths also
indicate different responsiveness to telomerase inhibitors.
Therefore, the cells with already short telomeres appear to be
ideal target cells for an anti-telomerase therapy [29, 30]. Given
that most APL patients have significant shortened terminal re-
striction fragment (TRF) lengths [31], APL may be a good
candidate for a therapeutic intervention with telomerase inhib-
itors. In order to investigate the efficiency of telomerase inhi-
bition inAPL, bothAPL cell lines NB4 andHL-60were treated
with telomerase inhibitor MST-312.
MST-312 is a chemically modified derivative of epigallocat-
echin gallate (EGCG), a major catechin of green tea. As com-
pared with EGCG, MST-312 possesses prominent advantages
in terms of chemical stability, the effective dose for the induc-
tion of telomere shortening, and the circumvention of acquired
resistance [32]. Although previous studies have shown that
MST-312 inhibits telomerase activity in tumor cells [32–34],
its mode of mechanism is yet to be fully understood.
In the present study, we demonstrated that treatment of
APL cells with telomerase inhibitor MST-312 is sufficient to
induce G2/M cell cycle arrest and apoptosis. Moreover, inhi-
bition of telomerase activity was accompanied with downreg-
ulation of NF-κB and NF-κB-regulated gene products.
Materials and methods
Cell culture and MST-312 treatment
APL cell lines, NB4 and HL-60, were cultured in suspension
in RPMI 1640 medium supplemented with 2 mM L-
glutamine, 10 % fetal bovine serum (FBS), 100 units/ml pen-
icillin, and 100 μg/ml streptomycin in a humidified atmo-
sphere of 5 % CO2 at 37 °C. Normal human peripheral blood
mononuclear cells (PBMCs) were isolated from heparinized
blood of healthy donors by density gradient centrifugation on
Lymphodex (Inno-Train Diagnostik, Kronberg, Germany)
and cultured in the same condition used for APL cells. Stock
solution of MST-312 (Sigma-Aldrich, USA) was prepared in
dimethyl sulfoxide (DMSO), and suitable working concentra-
tion was made from the stock using complete medium. For
MST-312 treatment, APL and PBMC cells were treated with
relevant amounts of MST-312 working solution to achieve
concentrations of 0.5, 1, and 2 μM.
Cell viability measured by trypan blue exclusion assay
To investigate the effect of MST-312 on cell viability, APL
cells (NB4 and HL-60) were subjected to trypan blue exclu-
sion assay. Briefly, cells were seeded into a 12-well culture
plate at a density of 2×105 cells/well and treated with various
indicated concentrations of MST-312. After treatment at dif-
ferent incubation times (24, 36, and 48 h), the cell suspension
was mixed with 0.4 % trypan blue solution at a 1:1 ratio. After
1–2-min incubation at room temperature, the mixture was
loaded onto one chamber of Neubauer hemocytometer and
squares of the chamber are observed under a light microscope.
The viable/live (clear) and non-viable/dead (blue) cells were
counted, and the viability was calculated using the formula
(number of live cells counted/total number of cells count-
ed)×100.
Metabolic activity measured by MTTassay
The effect of various concentrations ofMST-312 onmetabolic
activity of APL cells was assayed by the MTT colorimetric
method. Briefly, NB4 and HL-60 cells were seeded into a 96-
well culture plate (5×103 cells/well) and incubated with de-
sired concentrations of MST-312. Thirty-six hours after treat-
ment, the mediumwas removed and cells were incubated with
MTTsolution (5 mg/ml in PBS) for 4 h at 37 °C. The resulting
formazan crystals were solubilized by addition of 100 μL
dimethylsulfoxide (DMSO) at each well, and the absorbance
was measured at 570 nm by ELISA reader.
Cell cycle analysis
To explore the effect of MST-312 on cell cycle progression,
cells were subjected to DNA content/cell cycle analysis. Brief-
ly, cells were seeded into a 12-well culture plate at a density of
2×105 cells/well and incubated in presence of the various
indicated concentrations of MST-312 for 36 h. After incuba-
tion, cells were harvested, washed twice with PBS and fixed in
precooled 70 % ethanol overnight at −20 °C. After washing
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with PBS, the cells were treated with 0.5 μg/ml RNase in PBS
and incubated at 37 °C for 30 min before staining with
50 μg/ml propiduium iodide (PI) for 30 min. Then the cells
were analyzed using a FACScan flow cytometer (Becton
Dickinson).
Apoptosis assay
The effect of MST-312 on cell death of APL and PBMC cells
was assayed by apoptosis analysis. In brief, cells were seeded
into 12-well cell culture plates at a density of 2×105 cells/well,
and 36 h after MST-312 treatment, the cells were collected.
Then the cells were washed with PBS and stained using FITC
Annexin V Apoptosis Detection Kit II (BD Biosciences,
USA), according to the manufacturer’s instructions. The per-
centage of apoptotic cells was quantified using Becton–Dick-
inson FACS. Annexin V-positive and PI-negative cells were
considered to be in early apoptotic phase, and cells having
positive staining both for Annexin-V and PI were deemed to
undergo late apoptosis or necrosis.
Telomerase activity assay
The effect of MST-312 on telomerase activity was assayed by
the TeloTAGGG Telomerase PCR ELISA kit (Roche, Germa-
ny), according to the manufacturer’s instructions. The kit
method is a photometric enzyme immunoassay for the detec-
tion of telomerase activity, utilizing the telomeric repeat am-
plification protocol (TRAP). Briefly, cells were seeded into 6-
well cell culture plates at a density of 5×105 cells/well, and
36 h after MST-312 treatment, the cells were harvested. For
protein extraction, 2×105 cells were lysed in lysis buffer and
the protein extracts were subjected to TRAP assay. The kit
includes specific telomere primers bound to biotin, which al-
lows measuring the PCR-amplified telomerase products (and
the telomerase activity) by ELISA. In addition, the PCR prod-
ucts were also run through 12 % polyacrylamide gel
electrphoresis (PAGE) and the ladder was visualized by stain-
ing with silver nitrate.
Western blot analysis
Cell suspensions were centrifuged at 36 h afterMST-312 treat-
ment, and cell pellets were washed with cold PBS and lysed
(5×106 cells/aliquots) in 0.2 mL of RIPA buffer (10 mMTris–
HCl, pH 7.4, 150 mMNaCl, 5 mMEDTA, 1 % Triton X-100,
0.1 % sodium dodecyl sulfate, and 0.5 % sodium
deoxycholate) containing protease and phosphatase inhibitor
cocktails (Sigma). The cell lysate was centrifuged at 13,
000 rpm for 20 min at 4 °C, and the supernatant was collected.
Total protein of the supernatant was quantified using the Brad-
ford protein assay, and equal amounts of total cellular protein
were separated by 10% SDS–PAGE, according to the method
of Laemmli. The resolved proteins were then transferred from
the gels to nitrocellulose membranes (Hybond-ECL,
Amersham Corp). Afterward, membranes were incubated in
blocking buffer (1×Tris buffered saline [TBS], 0.1 % Tween-
20 with 5 % nonfat dry milk) for 1 h and probed overnight at
4 °C with specific primary antibodies (Cell Signaling Tech-
nology, UK) against cleaved caspase-3 (9664), caspase-9
(9502), cleaved PARP (5625), phospho-IκB (2859), and IκBα
(4814). After washing five times in 1×TBS containing 0.1 %
Tween-20 (TBST), membranes were incubated with horse
radish peroxidase (HRP)-conjugated secondary antibody for
1 h at room temperature. The immunoreactive proteins were
then visualized with a chemiluminescence detection system
(Amersham ECL Advance Kit, GE Healthcare) according to
the manufacturer’s protocol.
Nuclear fragmentation
The preparation of nuclear extracts was performed using the
Nuclear Extract Kit (Active Motif, Carlsbad, CA), according
to the manufacturer’s instructions. In brief, APL cells were
centrifuged at 36 h after MST-312 treatment and cellular pel-
lets were washed with 1 ml ice-cold PBS/phosphatase inhib-
itors, lysed in 250 μl hypotonic buffer, and then centrifuged at
14,000 rpm for 30 s at 4 °C. The cell pellets were resuspended
in 30 μl complete lysis buffer and centrifuged at 14,000 rpm
for 10 min at 4 °C. Finally, the supernatants (nuclear fraction)
were saved.
NF-κB DNA-binding assay
RNA isolation and preparation of cDNA
RNA from APL cells (NB4 and HL-60) was isolated at 36 h
after treatment with MST-312 by using TriPure Isolation Re-
agent according to the instructions of the manufacturer
(Roche). Reverse transcription (RT) reaction was performed
using the RevertAid First Strand complementary DNA
(cDNA) Synthesis kit from Fermentas. A 20-μl reaction
contained 9-μl nuclease-free water, 1 μl Random Hexamer
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The DNA-binding activity of NF-κB was quantified in the
APL cells by TransAM™ NF-κB p65 Transcription Factor
Assay Kit (Active Motif), according to the manufacturer’s
instructions. Briefly, equal amounts of the nuclear extracts
were incubated in 96-well plates coated with immobilized
oligonucleotide (5 -AGTTGAGGGGACTTTCCCAGGC-
3 ) containing a consensus (5 -GGGACTTTCC-3 ) binding
site for the p65 subunit of NF-κB. NF-κB binding to the target
oligonucleotide was detected by incubation with primary an-
tibody specific for p65 subunit and HRP-conjugated second-
ary antibody. For quantification of NF-κB activity, the optical
densities were measured at 450 nm by a microplate reader.
Primer, 4 μl 5× Reaction Buffer, 2 μl dNTP Mix (10 mM),
1 μl RiboLock RNase Inhibitor (20 U/μl), and 1 μl RevertAid
M-MuLV Reverse Transcriptase (200 U/μl) as a master mix,
and 2 μl of total RNA (1 μg per reaction) was added prior to
reaction start. Adapted times and temperature profiles for the
reverse transcription were used: incubation 5 min at 25 °C
followed by 60 min at 42 °C. The reaction was terminated
by heating at 70 °C for 5 min.
Quantitative real-time PCR
Real-time PCR was performed using 7.5 μl of RealQ Plus 2×
Master Mix Green (Ampliqon), 1.5 μl of the cDNA product,
1 μl of each of forward and reverse primers (10 pmol), and
4 μL of nuclease-free water in a total volume of 15 μl. Ther-
mal cycling conditions included an initial activation step at
95 °C for 15 min followed by 40 cycles including a denatur-
ation step at 95 °C for 15 s and a combined annealing/
elongation step at 60 °C for 60 s. The reaction took place in
the Rotor Gene 6000 Real-time PCR System (Corbett Re-
search). A melting curve analysis was performed to verify
the specificity of the products. The fold induction or
repression was measured relative to the control and calculated
after adjusting for the GAPDH reference gene using the com-
parative Ct (2−ΔΔCT) method. Primer sequences are available
upon request.
Statistical analysis
Two-tailed Student’s t test was used to determine if there is a
significant difference between experimental variables. A P
value <0.05 was considered statistically significant.
Results
MST-312 decreases cell viability and metabolic activity
of APL cells
The effect of various concentrations of MST-312 on cell via-
bility of APL cells was assessed by trypan blue exclusion
assay. As shown in Fig. 1a, the viability of NB4 and HL-60
cells after exposure toMST-312was reduced substantially in a
dose- and time-dependent manner. Over 50 % decrease in the
Fig. 1 MST-312 decreases cell viability and metabolic activity of APL
cells. a APL cells (NB4 and HL-60) were exposed with various
concentrations of MST-312, and cell viability was assessed by trypan
blue exclusion assay after different times of exposure (mean±SE, n=3).
The viability of APL cells after short-term exposure to MST-312 was
reduced substantially in a dose-dependent manner. b APL cells were
treated with various concentrations of MST-312 and metabolic activity
was assessed using MTT assay 36 h after treatment (mean±S.E., n=3).
The metabolic activity of APL cells exposed to MST-312 was
significantly decreased in a dose-dependent manner (*P<0.05;
**P<0.01, ***P<0.001, relative to cells untreated with MST-312)
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viability of treated cells was seen in 2 μM concentration of
MST-312 within 36 h, indicating a direct short-term cytotoxic
effect of MST-312 on APL cells. With consideration of severe
decrease in cell viability following longer exposure of MST-
312, the short-term exposure of 36 h was used in the following
experiments. To investigate the effect of MST-312 on meta-
bolic activity, APL cells were subjected to MTT colorimetric
method. As presented in Fig. 1b, cell metabolic activity which
is related to the number of viable cells was significantly de-
creased in APL cells treated with MST-312. The cytotoxic
effect of MST-312 was concentration-dependent, with ap-
proximately 5, 34, and 70 % reduction in metabolic activity
for NB4 cells and about 3, 25, and 65 % reduction for HL-60
cells after 36 h exposure to 0.5, 1, and 2 μM of MST-312,
respectively. Taken together, these findings suggest that MST-
312 could exert a dose-dependent short-term cytotoxic effect
on APL cells. In addition, NB4 cells appeared to be more
sensitive to cytotoxic effect of MST-312, compared with
HL-60 cells.
MST-312 leads to G2/M cell cycle arrest and increased
apoptotic sub-G1 population in APL cells
To better understand the mechanisms underlying the cytotoxic
effect of MST-312 on APL cells, we examined the effect of
MST-312 on the cell cycle. As illustrated in Figs. 2 and 3,
there was a significant increase in the number of cells at the
G2/M phase in both NB4 and HL-60 cells treated with 1 μM
concentration of MST-312 compared with control (untreated)
cells (P<0.05). Furthermore, the proportion of sub-G1 apo-
ptotic cells was also significantly increased after MST-312
treatment (P<0.05, 1 μM MST-312-treated cells compared
with untreated cells). Taken together, these findings suggest
Fig. 2 MST-312 leads to G2/M
cell cycle arrest and increased
apoptotic sub-G1 population in
NB4 cells. NB4 cells were treated
with various concentrations of
MST-312 for 36 h. The changes in
cell cycle phase distribution were
assessed by cell cycle analysis.
One representative experiment
among three independent assays
is shown
Tumor Biol. (2015) 36:8425–8437 8429
that MST-312 arrests APL cells at G2/M phase, thereby
inhibiting cell proliferation.
MST-312 promotes apoptosis in APL cells but not
in normal human PBMCs
In order to determine the effect of MST-312 on cell apoptosis,
APL cells were analyzed for Annexin-V binding and
Annexin-V combined with propiduium iodide (PI) by FITC
Annexin V Apoptosis Detection Kit II. As shown in Figs. 4
and 5, short-term incubation of APL cells with MST-312 sub-
stantially increased percentages of Annexin-V and Annexin-
V/PI double-positive cells in comparison to the untreated
cells, indicating acute apoptotic effect of MST-312 on APL
cells. The apoptotic effect was dose-dependent, with approx-
imately 34 % (total percentages of Annexin-V and Annexin-
V/PI double-positive cells) increase in apoptosis for NB4 cells
and 25 % increase for HL-60 cells after short-term (36 h)
exposure to l μM MST-312. This concentration of MST-312
was used in the following experiments.
To investigate the effect of MST-312 on cell death of
normal cells, human PBMCs were isolated, treated, and
analyzed by FITC Annexin-V Apoptosis Detection Kit
II. As presented in Fig. 6, we did not observe any
apoptotic effect of MST-312 on PBMCs using concen-
trations up to 2 μM in 36 h incubation.
MST-312 induces caspase activation in APL cells
To further assessment of apoptosis, we examined the
effect of MST-312 on caspase activation. APL cells
were treated with MST-312 for 36 h and then the
Fig. 3 G2/M cell cycle arrest and
increased apoptotic sub-G1
population in HL-60 cells treated
with MST-312. HL-60 cells were
treated with various
concentrations of MST-312 for
36 h. The changes in cell cycle
phase distribution were assessed
by cell cycle analysis. One
representative experiment of three
performed is presented
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expression of cleaved products of caspase-3, caspase-9,
and poly(ADP-ribose) polymerase (PARP) were assessed
using Western blot analysis. PARP is one of proteins
undergoing cleavage following caspase-3 activation. As
presented in Fig. 7, activation of caspase-3 and caspase-
9 and cleavage of PARP were observed in response to
MST-312. These findings indicated that MST-312 in-
duces apoptosis of APL cells in caspase-mediated
manner.
MST-312-induced telomerase inhibition is coupled
with suppression of the NF-κB activity
The effect of MST-312 on telomerase activity of APL cells
was assessed by TRAP assay. As shown in Fig. 8a, approxi-
mately 42 % reduction in telomerase activity for NB4 cells
and about 34 % reduction for HL-60 cells were observed after
36 h exposure to 1.0 μM of MST-312. To ascertain the mech-
anisms by which MST-312-induced telomerase inhibition
Fig. 4 Short-term (acute)
apoptotic effect of MST-312 on
NB4 cells. NB4 cells were treated
with various concentrations of
MST-312 for 36 h. Then, cells
were analyzed for Annexin-Vand
Annexin-V plus PI uptake by
flow cytometry. One
representative experiment of three
performed is shown (n=3,
*P<0.05; **P<0.01, relative to
cells untreated with MST-312)
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exerts short-term (acute) growth arrest and apoptosis, we in-
vestigate the effect ofMST-312 on NF-κB activity. Most stim-
uli activate NF-κB by IKK-mediated IκBα phosphorylation
and its degradation by the ubiquitin–proteasome pathway
allowing nuclear translocation of NF-kB and its subsequent
binding to DNA. Therefore, in order to investigate the NF-κB
activity, APL cells were treated with 1.0 μM of MST-312,
harvested after 36 h and then subjected to Western blotting
by the antibodies directed toward IκBα and phospho-IκB (at
Ser32). Western blot results revealed decreased expression of
phospho-IκB and increased expression of IκBα in treated
APL cells compared with untreated cells, indicating MST-
312-induced suppression of NF-κB activity in APL cells
(Fig. 8c). In addition, to verify whether NF-κB DNA-binding
activity is also repressed by MST-312, APL cells were sub-
jected to NF-κB DNA-binding assay. As presented in Fig. 8d,
the DNA binding of NF-κB decreased within 36 h following
the MST-312 treatment. Taken together, these findings sug-
gest that MST-312-induced telomerase inhibition is accompa-
nied with suppression of NF-κB activity.
MST-312-induced telomerase inhibition is accompanied
with downregulation of NF-κB-regulated anti-apoptotic
genes
With consideration ofMST-312-induced suppression of NF-κB
activity, we then examined whether MST-312 affected anti-
apoptotic genes regulated by NF-κB. To this end, the APL cells
were treated with MST-312, harvested for 36 h after treatment
and then analyzed for the expression of survivin, Bcl-2 and
Mcl-1 anti-apoptotic genes using quantitative real-time PCR.
As shown in Fig. 9, significant decreased expression of these
Fig. 5 MST-312 induces acute
apoptosis in HL-60 cells. HL-60
cells were treated with different
concentrations of MST-312 for
36 h. Then, cells were analyzed
for Annexin-V and Annexin-V
plus PI uptake by flow cytometry.
One representative experiment
among three independent assays
is shown (n=3, *P<0.05;
**P<0.01, relative to cells
untreated with MST-312)
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anti-apoptotic genes was seen in APL cells treated with MST-
312, compared with untreated cells. This finding revealed
MST-312-induced downregulation of anti-apoptotic NF-κB
target genes in APL cells, thereby promoting apoptosis.
MST-312 downregulates the expression of c-Myc
and hTERT genes
Telomerase regulation occurs mainly at the level of transcrip-
tion of hTERT [35]. A growing body of data indicates that
various transcription factors act on the hTERT promoter,
resulting in regulation of its expression [36]. Among the
transcription factors, c-Myc is thought to be a strong regulator
of hTERT gene transcription [37]. On the other hand, both c-
Myc and hTERT are target genes of NF-κB [38–40]. With
consideration of inhibitory effect of MST-312 on NF-κB ac-
tivity, we wished to investigate the transcriptional alterations
of hTERT and c-Myc following MST-312 treatment. As pre-
sented in Fig. 10, there was a significant decrease in hTERT
and c-Myc gene expression following 1.0 μMMST-312 treat-
ment for 36 h. Taken together, MST-312-induced downregu-
lation of c-Myc and hTERT and subsequent decreased telo-
merase activity may enhance the telomerase inhibitory effect
of MST-312.
Fig. 6 MST-312 does not induce
cell death in normal human
PBMCs. PBMCs were treated
with various concentrations of
MST-312 for 36 h. Then, cells
were analyzed for Annexin-Vand
Annexin-V plus PI uptake by
flow cytometry. One
representative experiment of three
performed is shown
Fig. 7 MST-312-induced
caspase activation in APL cells.
APL (NB4 and HL-60) cells were
treated with 1 μM concentration
of MST-312 for 36 h. Then, equal
amounts of cell lysates (80 μg)
were subjected to electrophoresis
and analyzed by Western blot for
cleavage of caspase-3, caspase-9,
and PARP. Actin serves as
loading control. The immunoblot
is representative of three
independent experiments
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Discussion
Since telomerase is constitutively expressed in the vast major-
ity of human cancers, telomerase-targeted therapy has been
considered as one of the most promising approaches for can-
cer treatment [26]. In this setting, various types of anti-
telomerase drugs are now in phase I and II clinical trials [41,
42]. MST-312 is a telomerase inhibitor that has emerged as a
promising candidate for telomerase-targeted therapy [32]. Pre-
vious studies in brain and lung tumors have indicated that
there are two different effects for MST-312, depending on
the time of exposure [34, 43]. Acute (short-term) effect, which
occurs following short-term (72 h) exposure with MST-312,
leads to DNA damage, ATM-dependent G2/M cell cycle
Fig. 8 MST-312-induced telomerase inhibition is coupled with
suppression of NF-κB activity. a APL (NB4 and HL-60) cells were
treated with 1 μM MST-312. After 36 h, cells were harvested and
telomerase activity was measured by PCR/ELISA-based TRAP assay
using TeloTAGGG Telomerase PCR ELISA kit, according to the
manufacturer’s instructions. Percentage of telomerase inhibition was
calculated by comparing telomerase activity of MST-312-treated cells
with telomerase activity of untreated cells. b PCR products of TRAP
assay were run through 12 % polyacrylamide gel electrphoresis (PAGE)
and the ladder was visualized by staining with silver nitrate. An extract of
the telomerase-positive cell line 293 as positive control (PC) and a cell
extract treated with DNase-free RNase as negative control (NC) were
included in experiment. c APL cells were treated with 1 μM
concentration of MST-312. After 36 h, cells were harvested and
subjected to immunoblot analysis using IκB antibody and phospho-
specific antibody against IκB phosphorylated at Ser32. As a loading
control, actin level was determined. One representative experiment of
three is shown. d APL cells were treated with 1 μM MST-312 for 36 h.
Then, cells were harvested and the nuclear fraction was separated using
Nuclear extraction kit. NF-κB DNA binding activity was quantified by
enzyme-linked immunosorbent assay using the TransAM NF-B p65
transcription factor assay kit, according to the manufacturer’s
instructions. Values represented as mean±S.E. (n=3, *P<0.05, relative
to cells untreated with MST-312)
Fig. 9 MST-312 decreases the expression of antiapoptotic genes
regulated by NF-κB. APL (NB4 and HL-60) cells were treated with
1 μM MST-312 for 36 h. Subsequently, RNA was isolated and cDNA
synthesis was performed. The result of Sybr-green real-time PCR using
specific primers has been shown. All values were normalized to GAPDH
(n=3, *P<0.05; **P<0.01, relative to cells untreated with MST-312)
8434 Tumor Biol. (2015) 36:8425–8437
arrest, and reduced cell viability. This effect is independent of
telomere erosion and mediated by uncoupling of the telome-
rase complex from the telomere DNA which is then recog-
nized as DNA-double strand breaks by the ATM-pathway.
Long-term (more than 1.5 months) treatment with MST-312
leads to a long-term effect, with significant telomere shorten-
ing. Consistent with previous findings, we also indicated that
short-term treatment with MST-312 induced G2/M cell cycle
arrest with decreased cell viability in APL cells (Figs. 1, 2, and
3). In addition, we observed increased apoptotic cells (Sub-G1
population) following acute telomerase inhibition (Figs. 2 and
3). Furthermore, our apoptosis analysis confirmed short-term
apoptotic effect of MST-312 on APL cells (Figs. 4 and 5).
However, no such effects in terms of cytotoxicity and apopto-
sis were observed in normal human PBMCs (Fig. 6), suggest-
ing tumor-selective growth inhibitory effect of MST-312.
Similar to MST-312, telomerase inhibition using anti-sense
oligonucleotides [44, 45] or G-quadruplex compounds [46]
also exerts short-term cytotoxic effects on tumor cells, inde-
pendent of critical telomere erosion. Since the acute effects of
telomerase inhibition are unrelated to telomere attrition, this
suggests telomerase might have functions in addition to telo-
mere maintenance [47].
Increasing evidence has highlighted non-canonical (non-
telomeric) activities of telomerase that are independent of its
conventional function in telomere maintenance [10–12]. The-
se activities included regulation of cell cycle and gene expres-
sion [12–15], inhibition of apoptosis [16–18], and modulation
of cellular signaling such as NF-κB [19, 20]. To clarify the
mechanisms by which telomerase inhibition exerts acute
growth arrest and apoptosis, the effect of telomerase inhibitor
on the NF-κB signaling, a critical pro-survival pathway, was
examined. We demonstrated here for the first time that the
telomerase inhibitor MST-312 has an anti-NF-κB activity on
APL cells. Our Western blot analysis showed suppression of
NF-κB activity following short-term administration of MST-
312, through decrease of IκB phosphorylation and its subse-
quent degradation (Fig. 8c). In addition, we verified that
NF-κB DNA-binding activity also is repressed by MST-312
(Fig. 8d), resulting in supression of genes regulated by NF-κB
such as antiapoptotic (survivin, Bcl-2, Mcl-1), proliferative (c-
Myc), and telomerase-related (hTERT) genes (Figs. 9 and 10).
Repression of NF-κB signaling and subsequent downregula-
tion of the pro-survival genes may be a possible explanation
for MST-312-induced acute growth arrest and apoptosis.
Deregulation and overexpression of both NF-κB and telo-
merase has been frequently found in human malignancies.
Earlier studies have implied upregulation of hTERT expres-
sion by NF-κB [38, 39]. On the other hand, recent study per-
formed by Ghosh et al. suggested that hTERT directly regu-
lates NF-κB-dependent gene expression by binding to p65
and recruiting to a subset of NF-κB promoters, such as those
of IL-6, TNF-α, and IL-8 [19]. Importantly, Ding et al. recent-
ly showed that hTERT regulates the expression of NF-κB
target genes independent of its telomerase activity [48]. Inter-
estingly, it has been shown that MST-312 has no effect on
NF-κB signaling in telomerase-negative cells indicating the
telomerase-specific effect of this compound [19]. Thus, the
most straightforward interpretation of our results is that
telomerase-dependent NF-kB suppression induced by MST-
312 may contribute in apoptosis of APL cells.
In conclusion, we demonstrated that the telomerase inhibitor
MST-312 causes acute growth arrest and apoptosis in APL cells
through suppression of NF-κB activity. In addition, our find-
ings reinforce the notion that telomerase served as a modulator
of the NF-κB signaling pathway, in a manner independent of its
activity in telomere maintenance. Therefore, telomerase-
targeted therapy by MST-312 which targets both telomeric
(telomere maintenance) and non-telomeric (NF-κB activation)
activity of telomerase, may provide a promising approach for
treatment of APL and other telomerase-positive cancers.
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